Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Derivation and characterization of peripheral artery disease specific induced pluripotent stem cells

EF 2009-10

Résumé
In 2006, it was discovered that skin cells, and other adult cells, could be reprogrammed to have many of the same features as embryonic stem cells. These cells are called induced pluripotent stem cells (iPSCs). Specifically, these iPSCs are no longer limited to their originating cell type but can become any cell type in the human body. This discovery holds great promise for regenerative medicine because we can now create patient specific cells that may be able to restore function in diseased individuals and that won't be rejected by the patient's immune system. This is especially important for older patients that have low level of regenerating cells in their tissues and circulation. One such group is patients with peripheral artery disease (PAD). This growing population of older patients does not have enough blood flow to their extremities leading to pain and even limb loss. PAD is related to smoking, diabetes, inactivity and obesity. Improving the function or replacing diseased endothelium (the cells that line blood vessels) may be key to treating these patients. However, it is unclear if cells from diseased patients can truly become healthy cells through the process of reprogramming. Can we really erase the damage of decades of smoking and inactivity? We plan to take skin cells from PAD patients and reprogram them into iPSCs and then differentiate these cells into the endothelium. We will test if these newly created endothelial cells show the same disease characteristics as would be found in PAD patients or if these cells behave like newly formed endothelium. If the resulting cells are healthy this would be a good indicator for their use in the clinic to restore blood flow in PAD patients. If the resulting cells demonstrate the disease phenotype then this means that these cells would be a valuable resource for studying the disease and that further intervention would be needed before they would be useful in the clinic.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
193786
Name
Hunter Arwen L
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Derivation and characterization of peripheral artery disease specific induced pluripotent stem cells
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Atherosclerosis; Endothelial Biology; Induced Pluripotent Stem Cells; Peripheral Artery Disease
Abstract
In 2006, it was discovered that skin cells, and other adult cells, could be reprogrammed to have many of the same features as embryonic stem cells. These cells are called induced pluripotent stem cells (iPSCs). Specifically, these iPSCs are no longer limited to their originating cell type but can become any cell type in the human body. This discovery holds great promise for regenerative medicine because we can now create patient specific cells that may be able to restore function in diseased individuals and that won't be rejected by the patient's immune system. This is especially important for older patients that have low level of regenerating cells in their tissues and circulation. One such group is patients with peripheral artery disease (PAD). This growing population of older patients does not have enough blood flow to their extremities leading to pain and even limb loss. PAD is related to smoking, diabetes, inactivity and obesity. Improving the function or replacing diseased endothelium (the cells that line blood vessels) may be key to treating these patients. However, it is unclear if cells from diseased patients can truly become healthy cells through the process of reprogramming. Can we really erase the damage of decades of smoking and inactivity? We plan to take skin cells from PAD patients and reprogram them into iPSCs and then differentiate these cells into the endothelium. We will test if these newly created endothelial cells show the same disease characteristics as would be found in PAD patients or if these cells behave like newly formed endothelium. If the resulting cells are healthy this would be a good indicator for their use in the clinic to restore blood flow in PAD patients. If the resulting cells demonstrate the disease phenotype then this means that these cells would be a valuable resource for studying the disease and that further intervention would be needed before they would be useful in the clinic.
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hunter, Arwen L
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~